Metastatic basal cell carcinoma: Rapid symptomatic response to cisplatin and paclitaxel

Michael Jefford, John D. Kiffer, Gino Somers, Fredy J. Daniel, Ian D. Davis

Research output: Contribution to journalReview ArticleResearchpeer-review

53 Citations (Scopus)


Background: Basal cell carcinoma (BCC) is the most common cancer in the community, although it rarely metastasizes. The literature reports less than 100 patients who have received chemotherapy for metastatic BCC. A further case of this rare disease is reported here. The pattern of disease in the reported patient was similar to that described in the literature, but the patient experienced a long period with untreated metastatic disease compared with that in the literature. Method: The patient was treated with cisplatin in combination with paclitaxel. Literature review suggests this to be the first report of this combination. Results: Rapid symptomatic response was achieved though late neurotoxicity occurred. Conclusion: This regimen is an active combination for the rare patient with metastatic BCC. The combination of carboplatin and paclitaxel causes less neurotoxicity and may therefore be a superior regimen.

Original languageEnglish
Pages (from-to)704-705
Number of pages2
JournalANZ Journal of Surgery
Issue number8
Publication statusPublished - 1 Aug 2004


  • Basal cell neoplasms
  • Cisplatin
  • Metastasis
  • Non-small-cell lung carcinoma
  • Paclitaxel
  • Palliative care

Cite this